DrugAug 6, 2014
Pfizer Cardura XL recall — FDA D-1485-2014
Failed Impurities/Degradation Specifications: Product from this lot may not meet specifications for a product degradant.
Class IIIFDA: TerminatedPfizer Inc.
Recall history in this database
Classification mix: Class II: 48, Class III: 29, Class I: 15.
DrugJul 23, 2014
VIRACEPT (R) (nelfinavir mesylate) Tablets, 625 mg, 120-count bottle recall — FDA D-1443-2014
Labeling: Incorrect or missing lot and or Exp Date: The bottles were labeled with an incorrect expiry date 11/2016. The correct expiry date is 09/2016.
Class IIIFDA: TerminatedPfizer Inc.
DrugJun 11, 2014
FLUCONAZOLE GREENSTONE BRAND fluconazole for Oral Suspension, ORANGE FLAVORED, 40 mg/mL recall — FDA D-1356-2014
Defective Container: Tamper evident ring failures discovered on some bottles.
Class IIFDA: TerminatedPfizer Inc.
DrugApr 30, 2014
Pfizer Tikosyn (dofetilide) 500 mcg (0.5mg) capsules, 60-count bottle recall — FDA D-1253-2014
Presence of Foriegn Tablets/Capsules: A single Tikosyn (dofetilide) 250 mcg capsule was discovered in one bottle of Tikosyn (dofetilide) 500 mcg (0.5 mg).
Class IIFDA: TerminatedPfizer Inc.
DrugJan 22, 2014
Zithromax recall — FDA D-745-2014
Failed Impurities/Degradation Specifications: Pfizer is recalling certain lots due to out of specification results for azithromycin N-oxide degradant.
Class IIIFDA: TerminatedPfizer Inc.
DrugJul 10, 2013
Pfizer Prempro recall — FDA D-630-2013
Failed Dissolution Specifications: Pfizer Inc. is recalling PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets) because certain lots for this product may not meet the…
Class IIIFDA: TerminatedPfizer Inc.
DrugJul 10, 2013
Pfizer Prempro recall — FDA D-631-2013
Failed Dissolution Specifications: Pfizer Inc. (Pfizer) is recalling PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets) because certain lots for this product may not meet…
Class IIIFDA: TerminatedPfizer Inc.
DrugJun 26, 2013
Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg recall — FDA D-607-2013
Failed Dissolution Specification
Class IIIFDA: TerminatedPfizer Inc.
DrugApr 24, 2013
Levoxyl (levothyroxine sodium) tablets, USP 75 mcg recall — FDA D-253-2013
Chemical contamination: emission of strong odor after package was opened.
Class IIFDA: CompletedPfizer Inc.
DrugApr 24, 2013
Levoxyl (levothyroxine sodium) tablets, USP 150 mcg recall — FDA D-259-2013
Chemical contamination: emission of strong odor after package was opened.
Class IIFDA: CompletedPfizer Inc.
DrugApr 24, 2013
Levoxyl (levothyroxine sodium) tablets, USP 88 mcg recall — FDA D-254-2013
Chemical contamination: emission of strong odor after package was opened..
Class IIFDA: CompletedPfizer Inc.
DrugApr 24, 2013
Levoxyl (levothyroxine sodium) tablets, USP 125 mcg recall — FDA D-257-2013
Chemical contamination: emission of strong odor after package was opened
Class IIFDA: CompletedPfizer Inc.
DrugApr 24, 2013
Levoxyl (levothyroxine sodium) tablets, USP 25 mcg recall — FDA D-251-2013
Chemical contamination: emission of strong odor after package was opened..
Class IIFDA: CompletedPfizer Inc.
DrugApr 24, 2013
Levoxyl (levothyroxine sodium) tablets, USP 100 mcg recall — FDA D-255-2013
Chemical contamination: emission of strong odor after package was opened..
Class IIFDA: CompletedPfizer Inc.
DrugApr 24, 2013
Levoxyl (levothyroxine sodium) tablets, USP 50 mcg recall — FDA D-252-2013
Chemical contamination: emission of strong odor after package was opened.
Class IIFDA: CompletedPfizer Inc.
DrugApr 24, 2013
Levoxyl (levothyroxine sodium) tablets, USP 112 mcg recall — FDA D-256-2013
Chemical contamination: emission of strong odor after package was opened.
Class IIFDA: CompletedPfizer Inc.
DrugApr 24, 2013
Levoxyl (levothyroxine sodium) tablets, USP 137 mcg recall — FDA D-258-2013
Chemical contamination: emission of strong odor after package was opened.
Class IIFDA: CompletedPfizer Inc.
DrugApr 24, 2013
Levoxyl (levothyroxine sodium) tablets, USP 175 mcg recall — FDA D-260-2013
Chemical contamination: emission of strong odor after package was opened.
Class IIFDA: CompletedPfizer Inc.
DrugApr 24, 2013
Levoxyl (levothyroxine sodium) tablets, USP 200 mcg recall — FDA D-261-2013
Chemical contamination: emission of strong odor after package was opened.
Class IIFDA: CompletedPfizer Inc.
DrugApr 3, 2013
TORISEL Kit (temsirolimus) injection, 25 mg/mL, CONCENTRATED recall — FDA D-219-2013
Lack of Assurance of Sterility; potential that a low level of endotoxins may be present in the diluent vials.
Class IIIFDA: TerminatedPfizer Inc.
Understanding this recall history
This page summarizes recall records in which the official source identifies Pfizer Inc. as the recalling firm or manufacturer. The number of records should not be treated as a safety rating or a measure of company size, because recall counts depend on product mix, reporting periods and how government records are organized.
Compare the dates, categories and classifications together rather than relying on the total alone. Open an individual record for the recalled product, reason, distribution details and current instructions available from the source.